Novo Nordisk
993.5 DKK -1.1%136 investors are following this company
Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.
Revenue
232.26B
EBIT %
44.16 %
P/E
53.21
Dividend yield-%
0.95 %
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
NOVO B
Daily low / high price
965.6 / 1,013.4
DKK
Market cap
4.44T DKK
Turnover
2.88B DKK
Volume
2.9M
Latest videos
Financial calendar
Interim report
07.08.2024
Interim report
06.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Novo Holdings AS | 28.3 % | 76.8 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss
Novo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity adline
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Novo Nordisk A/S - share repurchase programme
![Aktier i vælten: Zealand Pharma - hvorfor så kraftig en reaktion på tidlige data?](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/e68a2474-de22-4af4-bee5-779f8c63a800.png)
Aktier i vælten: Zealand Pharma - hvorfor så kraftig en reaktion på tidlige data?
Novo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease at the 84th Scientific Sessions of the American Diabetes Association
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
![Aktier i Vælten – Novo Nordisk: Hvorfor var regnskabet ikke nok?](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/e68a2474-de22-4af4-bee5-779f8c63a800.png)